Drug pricing regulator looking to make vital health supplements more affordable

India’s drug pricing regulator is contemplating capping costs of vital medicines like vitamin A, vitamin C, glycerine and anti-tetanus immunoglobulin to curb profiteering by the pharmaceutical corporations.

The National Pharmaceutical Pricing Authority (NPPA) proposes to invoke extraordinary powers in public curiosity, below para 19 of Drugs Prices Control Order (DPCO) 2013, for an indefinite interval to make them more affordable to sufferers, it has stated.

“The NPPA has been invoking para 19 in sure instances within the public curiosity to make medicine affordable with indefinite interval,” stated the minutes of the authority assembly. ET has seen the minutes of the assembly.

“Despite the truth that India is the pharmacy of the world, out-of-pocket bills on medicines is the most important trigger for pushing households past the poverty threshold; subsequently, there’s a want to make use of such provisions,” a senior official stated.

The transfer may affect a number of the main producers of those supplements equivalent to Abbott Laboratories, Bayer AG, GlaxoSmithKline, amongst others.

“The transfer can also be seemingly to face resistance from the pharma trade,” a pharma foyer professional stated, requesting anonymity.

Market information exhibits that vitamin and mineral complement launches in India have been on the rise. According to All India Organisation of Chemists and Druggists (AIOCD), the speedy improve within the variety of Covid-19 instances pushed the demand for immunity boosters like vitamin tablets by 30%-40%.

Doctors stated as Covid-19 instances elevated, folks began taking boosters as a precautionary measure as they’re deemed helpful for the immunity, together with decreasing the chance in respiratory infections. Even although there’s a lack of proof supporting the position of nutritional vitamins in Covid-19.

Earlier, in 2017, the drug pricing regulator had decreased the costs of stents by 87% and orthopaedic knee implants by invoking para 19 of Drugs Prices Control Order (DPCO) 2013 for a interval of 1 12 months. Subsequently, it was prolonged for one more 12 months. A report launched by the NPPA in 2020 revealed that value caps on cardiac stents imposed by the federal government had improved their accessibility.